Visceral leishmaniasis

This study tested a new drug called LXE408 in 101 adults and teens with visceral leishmaniasis, a serious parasitic disease. Participants received one of two LXE408 doses or a standard treatment. The goal was to see if LXE408 could clear the parasite and improve symptoms by day 2…

This early study tested whether the drug ivermectin could safely treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can appear after recovery from visceral leishmaniasis. Ten otherwise healthy adults with PKDL took ivermectin pills for five days each month fo…

This study tested a new drug called LXE408 in 52 adults with visceral leishmaniasis, a serious parasitic disease. The goal was to see if LXE408 could cure the infection by Day 28 compared to the standard treatment. The trial took place in Ethiopia and measured safety, drug levels…

This early study tested whether the common anti-parasite drug ivermectin could treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can spread a serious disease. Thirty people in Bangladesh received either ivermectin pills for 3 months or the standard drug milt…

This study tested two new types of biosensor platforms to detect viruses, bacteria, and parasites in blood and respiratory samples. The goal was to see if these devices could be accurate, fast, and cheap alternatives to standard lab tests. Researchers enrolled 149 adults with or …

This study compared a new generic version of liposomal amphotericin B (an antifungal drug) to the brand-name version (AmBisome®) in 58 healthy Chinese adults. Each volunteer received a single dose of both drugs at different times to see if the generic works the same way in the bo…

This study checked if a new version of the antifungal drug amphotericin B liposome works the same as the original. 42 healthy adults received a single dose of each version at different times. The goal was to see if the drug levels in the blood were similar enough to consider the …